HC Wainwright Reiterates Buy Rating on Absci Corporation
HC Wainwright maintains its buy rating on Absci Corporation with a $16 price target, a 39.86% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on Absci Corporation (ABSI) with a $16 price target on June 25, 2026.
- HC Wainwright's $16 price target implies 39.86% upside from Absci Corporation's ($ABSI) current $11.44 share price.
- Shares of Absci Corporation traded at $9.64 on Thursday with a market cap of approximately $1.31 billion.
- Absci Corporation, a biotech firm, has seen insider buying and multiple analysts maintaining buy ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 25, 2026, HC Wainwright reiterated its buy rating on Absci Corporation (NasdaqGS: ABSI), maintaining a price target of $16. Analyst Swayampakula Ramakanth continues to see potential in the biotechnology company.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Absci Corporation Stock Up 31.3%
Shares of NasdaqGS:ABSI traded near $9.64 on Thursday. Absci Corporation has a market capitalization of about $1.31 billion and a beta of 2.457, indicating higher volatility compared to the market. The stock has a 52-week low of $2.24 and a high of $8.57, with a 50-day moving average of $5.29 and a 200-day moving average of $3.71. The company holds a strong current ratio of 6.589, suggesting good liquidity.
$ABSI price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 25, 2026, HC Wainwright & Co. maintained its buy rating on Absci Corporation with a $16 price target. Just a day earlier, Needham reiterated its buy rating with an $11 target, while BTIG maintained a buy rating at $13. Guggenheim also maintained a buy rating on June 15, 2026, with a $15 target. Overall, Absci Corporation has a strong buy consensus with a mean price target of $9.61 among 10 analyst opinions.
Insider Buying and Selling at Absci Corporation
Several insiders have shown confidence in Absci Corporation by purchasing shares on June 4, 2026. Mary Szela bought 33,200 shares, followed by another purchase of 8,400 shares. Karen McGinnis also acquired 10,100 shares and later an additional 39,800 shares. Menelas Pangalos purchased 39,800 shares as well. These transactions were not part of any pre-planned trading program.
Other Institutional Activity in Absci Corporation
FMR LLC slightly increased its holdings by 168,995 shares, reaching 22,550,997 shares valued at about $67.65 million. ARK Investment Management LLC added 1,175,370 shares, boosting its position by 9.4% to 13,726,169 shares worth approximately $41.18 million. BlackRock, Inc. trimmed its stake by 78,238 shares, now holding 11,255,194 shares valued at around $33.77 million. Meanwhile, State Street Corp significantly increased its position by 1,333,981 shares, a 22.3% rise, reaching 7,324,858 shares worth about $21.97 million. Vanguard Capital Management LLC opened a new position with 5,886,640 shares valued at roughly $17.66 million.
About Absci Corporation
Absci Corporation is a biotechnology company based in Vancouver, Washington. Founded in 2011, it focuses on developing antibody therapeutics. The company has several preclinical development programs targeting conditions like inflammatory bowel disease, androgenic alopecia, and oncology. Absci collaborates with partners like PrecisionLife and Memorial Sloan Kettering Cancer Center for research. Led by CEO Sean McClain, the company employs about 140 people.
Bottom Line
HC Wainwright's reiterated buy rating and $16 price target reflect ongoing confidence in Absci Corporation's potential in the biotech sector. Investors should note that these ratings are based on past performance and strategic partnerships. Institutional activity and insider buying further highlight the interest in Absci's growth prospects.
Get Absci Corporation alerts
New 13F filings, insider trades, and analyst moves on $ABSI, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.